Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Eur J Contracept Reprod Health Care ; 21(4): 276-84, 2016 Aug.
Article in English | MEDLINE | ID: mdl-27220697

ABSTRACT

OBJECTIVES: This observational, multicentre, prospective phase IV study examined change in health-related quality of life (QOL) from baseline to 6 months in women initiating combined oral contraception (COC) based on natural estrogen. METHODS: Eligible women attending a baseline and 6-month gynaecology appointment belonged to one of three groups: group 1 used barrier contraception (condoms) and elected to continue this method; group 2 used condoms and elected to switch to COC based on natural estrogen; group 3 used COC based on ethinylestradiol and elected to switch to COC based on natural estrogen. The Spanish Society of Contraception (SEC)-QOL scale assessed health-related QOL. Secondary outcomes included symptoms of premenstrual syndrome, intermenstrual bleeding, duration and intensity of menstrual bleeding, contraception continuation rate, and tolerability. RESULTS: A total of 857 women were enrolled and 785 completed the study. Group 2 (n = 224 completed) had significantly lower SEC-QOL global and dimension scores at baseline and significantly greater increases in SEC-QOL from baseline to 6 months compared with groups 1 (n = 72) and 3 (n = 489). Group 3 reported a similar SEC-QOL score to that of group 1 at baseline but showed significantly greater improvement in SEC-QOL global and psychological scores from baseline to 6 months. Among women receiving COC based on natural estrogen, the contraception continuation rate was 713/780 (91.4%); treatment-related adverse events were reported by 13/780 (1.7%). CONCLUSIONS: Improved SEC-QOL after 6 months was found in women who were dissatisfied with their current contraception at baseline and chose to switch to COC based on natural estrogen.


Subject(s)
Contraceptives, Oral, Combined/therapeutic use , Ethinyl Estradiol/therapeutic use , Megestrol/analogs & derivatives , Nandrolone/analogs & derivatives , Patient Satisfaction , Quality of Life , Adolescent , Adult , Condoms/statistics & numerical data , Contraceptives, Oral, Combined/adverse effects , Ethinyl Estradiol/adverse effects , Female , Humans , Megestrol/adverse effects , Megestrol/therapeutic use , Metrorrhagia/chemically induced , Middle Aged , Nandrolone/adverse effects , Nandrolone/therapeutic use , Premenstrual Syndrome/chemically induced , Prospective Studies , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...